ASH Data On CRS Helps Determine Where Anti-CD20 Bispecifics Fit Versus CAR-T
From the CD20-directed bispecific antibody studies presented at ASH, the risk and severity of cytokine release syndrome is being viewed as a way to determine whether the bispecifics will be used before, after or instead of CAR-Ts.
You may also be interested in...
The company has maintained faith in autologous CAR-Ts, and its latest data show early signs of strong efficacy and favorable tolerability, possibly enabling outpatient use.
MEI/Kyowa Kirin will no longer seek accelerated approval based on a single-arm study as the FDA is calling for Phase III data due to growing conservatism regarding the PI3K class.
Roche has enjoyed decades-long success with its string of CD20-targeting drugs – and thanks to a legacy opt-in, so has Biogen.